Adaptimmune Therapeutics plc American (ADAP) Debt by Year
Adaptimmune Therapeutics plc American carried $50.2M in long-term debt against $91.1M in cash and equivalents at the end of fiscal year 2024. The table below carries 12 fiscal years, from 2013 to 2024, and the quarters Adaptimmune Therapeutics plc American has filed alongside them.
Annual figures, oldest first. Point at a bar to read its period.
ADAP Debt & Cash by Fiscal Year
Figures are as reported in USD. Each change compares the year with the year before it, and each column links to the filing it was taken from.
| Metric | FY24 | FY23 | FY22 | FY21 | FY20 | FY19 | FY18 | FY17 | FY16 | FY15 | FY14 | FY13 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Long-Term Debt | $50.2M | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| Cash & Equivalents | $91.1M-36.7% | $144.0M+33.3% | $108.0M-28.0% | $149.9M+163.6% | $56.9M+12.8% | $50.4M-26.3% | $68.4M-18.6% | $84.0M-47.1% | $158.8M-30.7% | $229.0M+347.5% | $51.2M | N/A |
ADAP Debt & Cash by Quarter
Figures are as reported in USD. Each change compares the quarter with the same quarter a year earlier.
| Metric | Q2'2510-Q | Q1'25 | Q4'2410-Q | Q3'24 | Q2'2410-Q | Q1'24 | Q4'23 | Q3'23 | Q2'23 | Q1'23 | Q4'22 | Q3'22 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Long-Term Debt | $25.7M+2.9% | $25.4M | $50.2M | $49.9M | $25.0M | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| Cash & Equivalents | $26.1M-87.7% | $41.1M-70.8% | $91.1M-36.7% | $116.7M+29.6% | $211.8M+175.2% | $140.7M+17.4% | $144.0M+33.3% | $90.1M+14.0% | $77.0M-21.3% | $119.9M+33.9% | $108.0M-28.0% | $79.0M+84.1% |
What long-term debt means
Long-term debt is borrowing that falls due more than a year out, and the cash line beside it is what the company held on the same balance sheet date.
More Adaptimmune Therapeutics plc American financials
Frequently Asked Questions
What was Adaptimmune Therapeutics plc American's long-term debt in fiscal year 2024?
Adaptimmune Therapeutics plc American carried $50.2M in long-term debt against $91.1M in cash and equivalents at the end of fiscal year 2024.
What was Adaptimmune Therapeutics plc American's long-term debt in the most recent quarter?
Adaptimmune Therapeutics plc American (ADAP) reported $25.7M in long-term debt in Q2 2025. This represents an increase of 2.9% from the same quarter a year earlier.
What does long-term debt mean on a financial statement?
Long-term debt is borrowing that falls due more than a year out, and the cash line beside it is what the company held on the same balance sheet date. This page lists what Adaptimmune Therapeutics plc American (ADAP) reported on that line in every period on record.